Craig Hoesley, HIVR4P 2021: Intrarectal Microbicides for HIV Prevention (Part 1)
touchINFECTIOUSDISEASES caught up with Craig Hoesley (University of Alabama School of Medicine, Birmingham, AL, US) to discuss research into intrarectal microbicides for HIV prevention.
Part 2 of our discussion can be viewed here.
The abstract entitled: ‘A randomized, double blind, placebo-controlled, phase 1 safety and pharmacokinetic study of dapivirine gel (0.05%) administered rectally to HIV-1 seronegative adults (MTN-026)’ (OA16.05) was presented at the HIVR4P Virtual Conference 2021, 03 February 2021.
Questions:
- What are the current unmet needs in HIV prevention? (0:11)
- Could you give us a brief overview of the history and current status of intrarectal microbicides for HIV prevention? (1:25)
- What will be the likely impact of increased use of intrarectal microbicides on public health? (2:40)
Disclosures: Craig Hoesley has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of HIVR4P Virtual Conference 2021.